Ionis Pharmaceuticals (NASDAQ: IONS) holder to sell 1,171 shares via Rule 144

Rhea-AI Filing Summary

Ionis Pharmaceuticals shareholder has filed a notice of proposed sale under Rule 144 for 1,171 shares of common stock, with an aggregate market value of $93,680.00. The shares are to be sold through Morgan Stanley Smith Barney on or about 01/16/2026 on the NASDAQ exchange.

The securities were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation from Ionis Pharmaceuticals. The filing notes that total common shares outstanding are 161,137,930, providing context for the size of this planned sale relative to the company’s equity base.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	1171	93680.00	161137930	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			1171	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for IONS disclose?

The Form 144 discloses that a shareholder of Ionis Pharmaceuticals (IONS) intends to sell 1,171 shares of common stock under Rule 144, with an aggregate market value of $93,680.00.

How many Ionis Pharmaceuticals (IONS) shares are planned to be sold?

The filing shows a planned sale of 1,171 shares of Ionis Pharmaceuticals common stock, to be sold through Morgan Stanley Smith Barney on or about 01/16/2026.

How were the Ionis (IONS) shares in this Form 144 acquired?

The 1,171 shares were acquired as RSUs granted under the 2011 Equity Incentive Plan on 01/15/2026, with the nature of payment described as compensation from Ionis Pharmaceuticals.

What is the aggregate market value of the IONS shares to be sold?

The Form 144 lists an aggregate market value of $93,680.00 for the 1,171 Ionis Pharmaceuticals common shares proposed to be sold.

How many Ionis Pharmaceuticals (IONS) shares are outstanding according to this filing?

The Rule 144 notice states that the number of Ionis Pharmaceuticals common shares outstanding is 161,137,930, giving context for the size of the planned sale.

On which exchange and through which broker will the IONS shares be sold?

The filing indicates the shares are expected to be sold on NASDAQ through Morgan Stanley Smith Barney, 1585 Broadway, New York, NY 10036.